Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Êàðäèîëîãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé êàðäèîëîãîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #46  
Ñòàðûé 22.09.2009, 20:10
Igor73 Igor73 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 17.03.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 1,195
Ïîáëàãîäàðèëè 69 ðàç(à) çà 53 ñîîáùåíèé
Igor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Pankov Ïîñìîòðåòü ñîîáùåíèå
Èãîðü, ñîãëàñèòåñü, íåñêîëüêî ñòðàííî, ÷òî ñ ìîìåíòà Âàøåãî ïåðâîãî ïîñëàíèÿ "...Êðàéíå ìàëî ïîíèìàþ â ÿäåðíîé ìåäèöèíå..." äî óòâåðæäåíèÿ "Æèçíåñïîñîáíûé ìèîêàðä - ýòî êðàñèâàÿ è ýëåãàíòíàÿ, íî ãèïîòåçà..." â ýòîì òîïèêå ïðîøëî âñåãî 2 äíÿ. Âû çà ýòîò êîðîòêèé ñðîê ïîëíîñòüþ ðàçîáðàëèñü â ÿäåðíîé ìåäèöèíå? è äåëàåòå âûâîä, ÷òî îíà íå î÷åíü íóæíà? Èíòåðåñíî, çà÷åì æå òîãäà â ëþáîé ïðîñòåíüêîé àìåðèêàíñêîé áîëüíè÷êå ñòîèò ïîäîáíàÿ àïïàðàòóðà?
1. Êàê è ðàíüøå ïîíÿòèÿ íå èìåþ â ÿäåðíîé ìåäèöèíå.
2. Äàæå â ìûñëÿõ íå äîïóñêàë èäåþ î íåíóæíîñòè ÿäåðíîé ìåäèöèíû.
3. Âîïðîñîì íà âîïðîñ. À ÷òî ÿäåðíàÿ ìåäèöèíà çàíèìàåòñÿ òîëüêî äèàãíîñòèêîé æèçíåñïîñîáíîãî ìèîêàðäà?
Îòâåòèòü ñ öèòèðîâàíèåì
  #47  
Ñòàðûé 22.09.2009, 20:20
Igor73 Igor73 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 17.03.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 1,195
Ïîáëàãîäàðèëè 69 ðàç(à) çà 53 ñîîáùåíèé
Igor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òåïåðü î ñóòè âîïðîñà - î æèçíåñïîñîáíîì ìèîêàðäå.
1.  ãàéäå ïî ÀÊØ íàïèñàíî, ÷òî ÷åì íèæå ÔÂ, òåì áîëüøå ïîëüçà îò ÀÊØ.  ðÿäå èññëåäîâàíèé óñòàíîâëåíî, ÷òî "patients with an EF less than 0.35 from the CASS registry showed 5-year survival rates of 73%, 70%, and 62% in patients with an EF from 0.31 to 0.35, 0.26 to 0.30, and less than 0.25, respectively (554). A comparison between surgically treated and medically treated groups revealed the greatest surgical benefit in patients with an EF of 0.25 or less. The medically treated patients had a 5-year survival rate of 43% compared with 63% for those treated with coronary bypass surgery. A comparison study of 5824 patients who underwent medical or surgical therapy for ischemic heart disease in the Duke University Cardiovascular Database showd that patients with the worst LV function (EF less than 0.35) had the greatest 10-year survival benefit from bypass surgery (46% versus 27%). Patients with an EF of 0.35 to 0.50 had a 10-year survival rate of 62% in the surgical group versus 50% in the medical group (87)" ñòð. å393.
2. Íà ýòîé æå ñòðàíèöå íàïèñàíî, ÷òî ÀÊØ ïîêàçàíî ïàöèåíòàì ñ òÿæåëûì ïîðàæåíèåì êîðîíàðíûõ àðòåðèé è íèçêîé Ô òîëüêî ïðè óñëîâèè íàëè÷èÿ æèçíåñïîñîáíîãî ìèîêàðäà. È ÷òî îòäåëüíî ýòà ïðîáëåìà îáñóæäàåòñÿ â ðàçäåëå 9.
3. Ïåðåõîäèì ê ðàçäåëó 9. Òàì ñêàçàíî, ÷òî"if the patient has prominent signs and symptoms of CHF with minimal angina, the decision to operate should be based on objective evidence of hibernating myocardium (755)".
Ññûëêà 755. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
318 ïàöèåíòàì ñ ÔÂ<35% ñäåëàëè ñòðåññ-ÝõîÊà ñ äîáóòàìèíîì, äàëåå èõ âðà÷è íà îñíîâàíèè ðàçëè÷íûõ ïðèçíàêîâ ðåêîìåíäîâàëè ðåâàñêóëÿðèçàöèþ è â ñòàòüå îòêðûòî îá ýòîì íàïèñàíî - "The decision for revascularization was not randomized and was made by the patients’ physicians" è â çàâèñèìîñòè îò ðåçóëüòàòîâ ðàçäåëèëè èõ íà 4 ãðóïïû: åñòü æèâîé ìèîêàðä è âûïîëíåíà ðåâàñêóëÿðèçàöèÿ (1), åñòü æèâîé ìèîêàðä è íå âûïîëíåíà ðåâàñêóëÿðèçàöèÿ (2), íåò æèâîãî ìèîêàðäà+ðåâàñêóëÿðèçàöèÿ (3) è íåò æèâîãî ìèîêàðäà+íåò ðåâàñêóëÿðèçàöèè (4). Ïîñëå ýòîãî ìåñòà ÿ áû óæå äàëüøå ñòàòüþ íå ÷èòàë, ïîòîìó ÷òî ñëèøêîì ìíîãî ñáúåêòèâèçìà è ñëó÷àéíîñòåé ïðè òàêîì äèçàéíå ïðèäåòñÿ ó÷èòûâàòü. Íî ÷èòàåì äàëüøå - òàáëèöó èñõîäíîé õàðàêòåðèñòèêè âêëþ÷åííûõ ïàöèåíòîâ. Òàì íå óêàçàí õàðàêòåð ïîðàæåíèÿ êîðîíàðíûõ ñîñóäîâ. Òàêèì îáðàçîì, âðà÷è, óâèäåâ ñòâîë ËÊÀ ìîãëè âñåì ñîâåòîâàòü ðåâàñêóëÿðèçàöèþ è òàêèå ïàöèåíòû ïðîñòî äîëüøå æèëè. Ýòîò äåôåêò äèçàéíà ïðîñòî ñïðÿòàëè îò ÷èòàòåëÿ. Êîñâåííî, íà ýòî óêàçûâàåò ÿêîáû íåäîñòîâåðíûé ðîñò îò 1 ê 4 ãðóïïå ðîñò ÷èñëà ïàöèåíòîâ ñ 3-õ ñîñóäèñòûì ïîðàæåíèåì: îò 39% â 1 ãðóïïå äî 54% â 4. Äàëüøå, â ãðóïïå 1 äîñòîâåðíî ÷àùå îòìå÷àëàñü ñòåíîêàðäèÿ (54% ïðîòèâ 20% â ãðóïïå 4). Ìîæåò áûòü ðåøåíèå î ðåâàñêóëÿðèçàöèè ïðîñòî íàäî îñíîâûâàòü íà æàëîáàõ ïàöèåíòà è íå òðàòèòüñÿ íà PET? È íàêîíåö ñåé÷àñ ìíîãèìè ýêñïåðòàìè ïðèçíàåòñÿ íåçíà÷èòåëüíàÿ ðîëü ñòðåññ-ÝõîÊà â îïðåäåëåíèè "æèâîãî" ìèîêàðäà.
Âûâîä: ÿ áû íå ñòàë ïðèìåíÿòü â ðåàëüíîé êëèíè÷åñêîé ïðàòèêå ðåçóëüòàòû ñòîëü ñïîðíî ñïëàíèðîâàííîãî èññëåäîâàíèÿ.
4. Ñëåäóþùàÿ ôðàçà/öèòàòà èç ãàéäà "There should be demonstration of substantial regions of myocardial viability that would benefit from revascularization (756)"
Ññûëêà 756. Î÷åíü ïîõîæåå íà ïðåäûäóùåå èñëëåäîâàíèå èç ×åõèè - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
5. È íàêîíåö - "Such areas must be perfused by coronary arteries of sufficient size and location to be reasonable targets for bypass surgery (757)"
Ññûëêà 757. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
"Clinical data were collected retrospectively by chart review by use of predetermined definitions and a standardized data collection form". Ïðè âñåì óâàæåíèè ê àâòîðàì ðåòðîñïåêòèâíûå èññëåäîâàíèÿ íå ñîâñåì íàäåæíûé (ñîâñåì íå íàäåæíûé) èñòî÷íèê èíôîðìàöèè.
PS: âñå, ÷òî õîòåë ñêàçàòü, ñêàçàë. Ïðîäîëæåíèå äèñêóññèè ñ÷èòàþ îïàñíûì äëÿ ôîðóìà. Áåðó íà ñåáÿ îáÿçàòåëüñòâà íå ïèñàòü áîëüøå ñîîáùåíèé â ýòîé òåìå. Ó âñåõ, êîãî îáèäåë åùå ðàç ïðîøó ïðîùåíèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #48  
Ñòàðûé 22.09.2009, 20:27
Àâàòàð äëÿ Gilarov
Gilarov Gilarov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,196
Ïîáëàãîäàðèëè 713 ðàç(à) çà 691 ñîîáùåíèé
Gilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåGilarov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé äîêòîð Ïàíêîâ!
ÈÌÕÎ, íåò ñìûñëà ïðèäèðàòüñÿ ê ñëîâàì. ß ëè÷íî íå âèæó áîëüøîãî ïðîòèâîðå÷èÿ â ïðèâåäåííûõ Âàìè öèòàòàõ Èãîðÿ. Ïîêàçàíèÿ ê ðåâàñêóëÿðèçàöèè îïðåäåëÿþòñÿ íå òîëüêî (è ê ñòàòè, íå ñòîëüêî) êîëè÷åñòâîì æèçíåñïîñîáíîãî ìèîêàðäà, à ñêîðåå îáúåìîì ñàìîé çîíû èøåìèè. Ñîãëàñèòåñü, ó äîâîëüíî áîëüøîãî ÷èñëà áîëüíûõ, êîòîðûì îñóùåñòâëÿþò ðåâàñêóëÿðèçàöèè âåñü ìèîêàðä, ê ñ÷àñòüþ, æèçíåñïîñîáåí. Ñöèíòèãðàôèÿ - ãîðàçäî ìåíåå operator-depending ìåòîä, ÷åì ñòðåññ-Ýõî è, ñëåäîâàòåëüíî, áîëåå îáúåêòèâíûé. Îòòóäà è ðîñò ïîïóëÿðíîñòè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #49  
Ñòàðûé 22.09.2009, 21:01
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Igor73 Ïîñìîòðåòü ñîîáùåíèå
Èçâèíèòå, Åâãåíèé Íèêîëàåâè÷ ...  äàííîì ñëó÷àå åñòü ïðîòèâîðå÷èå â ñàìîì ãàéäå, ÿ âñåãî ëèøü îáðàòèë íà ýòî âíèìàíèå.
.
Íèêàêèõ ïðîòèâîëå÷èé â ãàéäå íåò. Âñå çàâèñèò îò òîãî, êàê åãî ÷èòàòü. À èìååíî - åñëè ó áîëüíîãî ñ ëþáûì ïîðàæåíèåì ê à ñèñòîëè÷åñêàÿ ô-öèÿ ñîõðàííà (íîðìàëüíàÿ Ô ËÆ) òî è íåò ñìûñëà îïðåäåëÿòü æèçíåñïîñîáíîñòü ìèîêàðäà. Ôóíêèîíèðóþøåãî ìèîêàðäà òàì äîñòàòî÷íî. Åñëè æå ñèñòîëè÷åñêàÿ ôóíêöèÿ ñíèæåíà, ìîæåò âîçíèêíóòü âîïðîñ - íàñêîëüêî áóäåò ýôôåêòèâíà ðåâàñêóëÿðèçàöèÿ? Îòâåò íà íåãî, ïîìèìî òåõíè÷åñêèõ ïðîáëåì ñàìîé ðåâàñêóëÿðèçàöèè, ýòî çàâèñèò îò òîãî, ñêîëüêî ìèîêàðäà îñòàëîñü è â êàêîì îí ñîñòîÿíèè? Äëÿ òåðàïèè ýòî íå èìååò îñîáîãî çíà÷åíèÿ (ïðîñòî ðèñêà îñëîæíåíèé áîëüøå åñëè â çîíå èøåìè÷åñêîé äèñôóíêöèè ìèîêàðä ñîõðàíèëñÿ), à äëÿ õèðóðãèè - íåïîñðåäñòâåííîå, êàê äëÿ ðåâàñêóëÿðèçàöèè (÷òîáû íå íàäåÿòüñÿ íà "÷óäåñà") òàê è äëÿ ðåçåêöèè. Ðèñê õèðóðãè÷åñêîãî âìåøàòåëüñòâà îïðàâäàí ëèøü òîãäà, êîãäà åñòü ìèîêàðä, êîòîðûé îòâåòèò íà ðåâàñêóëÿðèçàöèþ. Âñå ëîãè÷íî è ãàéäàì íèêàê íå ïðîòèâîðå÷èò. Ãäå Âû íàøëè ïðîòèâîðå÷èÿ? Ìîæåò ÷èòàëè íåâíèìàòåëüíî?

Öèòàòà:
Ñîîáùåíèå îò Igor73 Ïîñìîòðåòü ñîîáùåíèå
â ãàéäå ïî ÀÊØ îò 2004 ãîäà ... îòñóòñòâèå "æèâîãî" ìèîêàðäà òàì íå óêàçàíî, êàê ôàêòîð ðèñêà..
Âîò ýòî âîîáùå çàìå÷àòåëüíî! Ïðîñòî øåäåâð! À â ãàéäàõ, ñëó÷àéíî, íå íàïèñàíî ñ êàêîé öåëüþ äåëàåòñÿ ýòà ñàìàÿ ÀÊØ? Ïðîñòî ïîòîìó ÷òî ñëîâî êðàñèâîå? Êàêîâà öåëü ïðîöåäóðû? Íàñêîëüêî ìíå èçâåñòíî öåëü ÀÊØ -ÐÅÂÀÑÊÓËßÐÈÇÀÖÈß - Íî, ðåâàñêóëÿðèçàöèÿ ÷åãî? ×òî ðåâàñêóëÿðèçèðóþò? Íåóæåëè äëÿ òîãî, ÷òîáû ïîíÿòü, ÷òî ðåâàñêóëÿðèçèðóþò èìåííî "æèâîé" ìèîêàðä íàäî îáÿçàòåëüíî ÷òîáû îá ýòîì â ãàéäàõ íàïèñàëè è ïðîâåëè êàêîå-ëèáî ÷óäî-èññëåäîâàíèå? Ïðîñòîãî ñðåäíåãî îáÿçàòåëüíîãî îáðàçîâàíèÿ äëÿ ýòîãî íå äîñòàòî÷íî? Íèêîãäà íå ñëûõàëè ïðî òàêèå ñèòóàöèè, êîãäà õèðóðãè îòêðîþò ïåðèêàðä - à òàì âìåñòî ìûøöû ëåâîãî æåëóäî÷êà ñïëîøíûå ðóáöû ïî âñåé áîêîâîé è äðóãèì ñòåíêàì? Êàê Âû äóìàåòå, ÷åì çàêàí÷èâàþòñÿ òàêèå îïåðàöèè?

Öèòàòà:
Ñîîáùåíèå îò Igor73 Ïîñìîòðåòü ñîîáùåíèå
Ê ñîæàëåíèþ, èíôîðìàöèè äëÿ ïðèíÿòèÿ ðåøåíèÿ íåäîñòàòî÷íî. Íåò äàííûõ ÊÀÃ, íåò äàííûõ î ñàìîì ïàöèåíòå.
Íó âîò, îïÿòü "öåïëÿåìñÿ çà ñîëîìèíêó". Êîíå÷íî, êðþ÷êîòâîðíûå äîâîäû ìîæíî ïðèâîäèòü äî áåñêîíå÷íîñòè. Íî â âûïèñêå ÿñíî íàïèñàíà ïðè÷èíà îòêàçà â õèðóðãè÷åñêîì ëå÷åíèè "Ïåðåñìîòðåíû è îöåíåíû äàííûå âñåõ èññëåäîâàíèé. Ðåøåíî, ÷òî ñåðäöå ïîñëå ÈÌ ñèëüíî ïîâðåæäåíî, íàáëþäàåòñÿ î÷åíü áîëüøîé ðóáåö, êîòîðûé çàíèìàåò áîëåå 70% âñåãî ËÆ, òàêæå åñòü àíåâðèçìà ñ ïðèñòåíî÷íûì òðîìáîì, ïî÷òè íå âèäíî çäîðîâîé ìûøöû ñåðäöà. Ðåêîíñòðóêòèâíàÿ îïåðàöèÿ íåâîçìîæíà" Ðàçâå íå ïîíÿòíî, ÷òî ïðè÷èíà îòêàçà - îòñóòñòâèå "æèâîãî" ìèîêàðäà? Èëè Âû âèäèòå çäåñü äðóãóþ ïðè÷èíó? Êàêóþ?

Íà ñàìîì äåëå ïðè ïóáëèêàöèè ýòîãî ñëó÷àÿ ó ìåíÿ áûëà è åùå îäíà öåëü - ïîêàçàòü Âàì, êàê îòëè÷àþòñÿ ðåçóëüòàòû èññëåäîâàíèÿ ìèîêàðäà â ýòîé âûïèñêå îò äåéñòâèòåëüíîãî ñîñòîÿíèÿ ìèîêàðäà ó ýòîãî áîëüíîãî. Ïî÷åìó åìó âñå-òàêè âûïîëíèëè îïåðàöèþ? Íî, áîþñü, ñ Âàìè äî ýòîãî íå äîéäó. Íå äîæèâó.
Îòâåòèòü ñ öèòèðîâàíèåì
  #50  
Ñòàðûé 22.09.2009, 21:30
Àâàòàð äëÿ audovichenko
audovichenko audovichenko âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.01.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,477
Ïîáëàãîäàðèëè 1,531 ðàç(à) çà 1,497 ñîîáùåíèé
audovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Åâãåíèé Íèêîëàåâè÷, Âû íàì äîðîãè ñî âñåõ òî÷åê çðåíèÿ, òàê ÷òî óæ, ïîæàëóéñòà, äîæèâèòå .

Äóìàþ, äåéñòâèòåëüíî, íåîáõîäèì íåáîëüøîé òàéì-àóò äëÿ ñíèæåíèÿ ãðàäóñà äèñêóññèè. Ãëàâíîå, ÷òî â öåëîì ìû âñå ãîâîðèëè îá îäíîì è òîì æå, ïðîñòî êòî-òî - áîëåå ïðîôåññèîíàëüíî, à êòî-òî - áîëåå èçäàëåêà.

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Cat îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #51  
Ñòàðûé 22.09.2009, 21:31
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Gilarov Ïîñìîòðåòü ñîîáùåíèå
Ñöèíòèãðàôèÿ - ãîðàçäî ìåíåå operator-depending ìåòîä, ÷åì ñòðåññ-Ýõî è, ñëåäîâàòåëüíî, áîëåå îáúåêòèâíûé.
Ðàçðåøèòå âñòðÿòü, Ìèõàèë Þðüåâè÷?
Êðîìå òîãî, ÷òî ýòîò ìåòîä ìåíåå çàâèñèì îò îïåðàòîðà, îí ïîçâîëÿåò âèçóàëèçèðîâàòü èìåííî òå êëåòêè ìèîêàðäà, êîòîðûå ìåòÿòñÿ. Êëåòêè, à íå ñòåíêó â öåëîì! Åñëè ýòî ïåðôóçèîííàÿ ñöèíòèãðàôèÿ - òî îáÿçàòåëüíî êëåòêè ñ ñîõðàííîé ìåìáðàíîé è íàëè÷èåì îáìåíà âåùåñòâ, ïîñêîëüêó ñàìè àãåíòû â ýòîì îáìåíå ó÷àñòâóþò è çàäåîæèâàþòñÿ èìåííî â "æèâûõ" êëåòêàõ. Âñå äðóãèå, íåèçîòîïíûå ìåòîäû, ïðè âñåé èõ çàìå÷àòåëüíîé ðàçðåøàþùåé ñïîñîáíîñòè íå ìîãóò äèôôåðåíöèðîâàòü ïîãèáøóþ òêàíü îò "æèâûõ" êëåòîê. Ïîýòîìó, êîãäà ãðàìîòíûé àìåðèêàíñêèé êàðäèîëîã òîëüêî ãëÿíåò íà ñöèíòèðãàììó âûñîêîãî ðèñêà -ðåøåíèå ïðèíèìàåò áåç ïðîìåäëåíèÿ.

Êîììåíòàðèè ê ñîîáùåíèþ:
Gilarov îäîáðèë(à):
audovichenko îäîáðèë(à): ý
Îòâåòèòü ñ öèòèðîâàíèåì
  #52  
Ñòàðûé 22.09.2009, 21:33
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò audovichenko Ïîñìîòðåòü ñîîáùåíèå
Åâãåíèé Íèêîëàåâè÷, Âû íàì äîðîãè ñî âñåõ òî÷åê çðåíèÿ, òàê ÷òî óæ, ïîæàëóéñòà, äîæèâèòå .
Àííà Åâãåíüåâíà, Âû äàæå íå ïðåäñòàâëÿåòå êàê ìíå áûëî ïðèÿòíî ýòî ïðî÷èòàòü!
Îòâåòèòü ñ öèòèðîâàíèåì
  #53  
Ñòàðûé 22.09.2009, 21:43
Àâàòàð äëÿ audovichenko
audovichenko audovichenko âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 26.01.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,477
Ïîáëàãîäàðèëè 1,531 ðàç(à) çà 1,497 ñîîáùåíèé
audovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaudovichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò ostroumov Ïîñìîòðåòü ñîîáùåíèå
Ðàçðåøèòå âñòðÿòü, Ìèõàèë Þðüåâè÷?
Êðîìå òîãî, ÷òî ýòîò ìåòîä ìåíåå çàâèñèì îò îïåðàòîðà, îí ïîçâîëÿåò âèçóàëèçèðîâàòü èìåííî òå êëåòêè ìèîêàðäà, êîòîðûå ìåòÿòñÿ. Êëåòêè, à íå ñòåíêó â öåëîì! Åñëè ýòî ïåðôóçèîííàÿ ñöèíòèãðàôèÿ - òî îáÿçàòåëüíî êëåòêè ñ ñîõðàííîé ìåìáðàíîé è íàëè÷èåì îáìåíà âåùåñòâ, ïîñêîëüêó ñàìè àãåíòû â ýòîì îáìåíå ó÷àñòâóþò è çàäåîæèâàþòñÿ èìåííî â "æèâûõ" êëåòêàõ. Âñå äðóãèå, íåèçîòîïíûå ìåòîäû, ïðè âñåé èõ çàìå÷àòåëüíîé ðàçðåøàþùåé ñïîñîáíîñòè íå ìîãóò äèôôåðåíöèðîâàòü ïîãèáøóþ òêàíü îò "æèâûõ" êëåòîê. Ïîýòîìó, êîãäà ãðàìîòíûé àìåðèêàíñêèé êàðäèîëîã òîëüêî ãëÿíåò íà ñöèíòèðãàììó âûñîêîãî ðèñêà -ðåøåíèå ïðèíèìàåò áåç ïðîìåäëåíèÿ.
Ãì, îäîáðÿëêà êàêàÿ-òî îáðóáëåííàÿ ïîëó÷èëàñü.

ß õîòåëà íàïèñàòü, ÷òî, íåñîìíåííî, ýòî òàê. Ïðîñòî â Ðîññèè ìåòîä ñöèíòèãðàôèè, ê âåëèêîìó ñîæàëåíèþ, äîñòóïåí íå âåçäå (ïðè÷èíû íåäîñòóïíîñòè ìîãóò áûòü ðàçíûå).
Îòâåòèòü ñ öèòèðîâàíèåì
  #54  
Ñòàðûé 23.09.2009, 05:59
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò audovichenko Ïîñìîòðåòü ñîîáùåíèå
Ãì, îäîáðÿëêà êàêàÿ-òî îáðóáëåííàÿ ïîëó÷èëàñü.

ß õîòåëà íàïèñàòü, ÷òî, íåñîìíåííî, ýòî òàê. Ïðîñòî â Ðîññèè ìåòîä ñöèíòèãðàôèè, ê âåëèêîìó ñîæàëåíèþ, äîñòóïåí íå âåçäå (ïðè÷èíû íåäîñòóïíîñòè ìîãóò áûòü ðàçíûå).
Êîíå÷íî, Àííà Åâãåíüåâíà, ó êàæäîãî ïðè÷èíû ìîãóò áûòü ðàçíûìè. Íî â ëèòåðàòóðå ìîæíî âñÿêîå âñòðåòèòü, â òîì ÷èñëå è îáîáùåíèå òàêèõ ïðè÷èí. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Nuclear cardiology is not widely performed in other Asian countries. This is unfortunate, especially when the large population bases of the region are considered... Most cardiologists in these countries prefer echocardiography as a screening test and coronary angiography as a final diagnostic test. Coronary angiography remains relatively inexpensive compared with radionuclide imaging. Nuclear medicine and specifically nuclear cardiology procedures are considered to be special tests and are performed in only a few large centers. Similar situations are seen in a number of other countries in Asia....Other problems facing nuclear cardiology in Asia are limited training opportunities and the fact that general cardiologists currently have a greater interest in intervention and echocardiography than in nuclear medicine techniques...
Îòâåòèòü ñ öèòèðîâàíèåì
  #55  
Ñòàðûé 23.09.2009, 10:14
Àâàòàð äëÿ dmblok
dmblok dmblok âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 05.11.2006
Ãîðîä: Msk
Ñîîáùåíèé: 1,827
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 67 ðàç(à) çà 62 ñîîáùåíèé
dmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådmblok ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
To Igor73.
À Âû âèäåëè òàêóþ ñòàòüþ:
Rizzello V - Heart - 01-FEB-2006
Long term prognostic value of myocardial viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic
cardiomyopathy undergoing coronary revascularisation

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

 çàùèòó îïðåäåëåíèÿ æèçíåñïîñîáíîñòè è, ãëàâíîå, äîáóòàìèí-ñòðåññ-ÝÕÎ.

Êîììåíòàðèè ê ñîîáùåíèþ:
ostroumov îäîáðèë(à): Åñëè ñ èçòîïàìè ïëîõî, òî äåâàòüñÿ íåêóäà...
Îòâåòèòü ñ öèòèðîâàíèåì
  #56  
Ñòàðûé 24.09.2009, 15:28
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 îæèäàíèè îòâåòîâ Èãîðÿ è åãî åäèíîìûøëåííèêîâ íà âîïðîñû, çàäàííûå ìíîþ â ïîñòå ¹ 49, â ñâÿçè ñ ïîæåëàíèÿìè êîëëåã ïðîäîëæèì ðàññìàòðèâàòü ñèòóàöèþ ñ íàøèì ïàöèåíòîì, âûïèñêà êîòîðîãî ïðåäñòàâëåíà â ïîñòå ¹ 30. Äëÿ òîãî, ÷òîáû ÷èòàòåëè â äàëüíåéøåì íå ïèñàëè î ñåáå «Êðàéíå ìàëî ïîíèìàþ â ÿäåðíîé ìåäèöèíå.» íà÷íåì ñ ãàéäîâ ïî ðàäèîèçîòîïíîé äèàãíîñòèêå â êàðäèîëîãèè. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
 ðàçäåëå 2. General Principles of Assessing Myocardial Viability by Radionuclide Techniques íà ñòðàíèöå 30 ìîæíî íàéòè âîò ýòî The radionuclide tracers and techniques most often used in this situation have been evaluated for their relation to preserved tissue viability directly, by correlating tracer uptake (of the single-photon tracers Tl-201 and sestamibi, and the metabolic tracer FDG) with histologically confirmed extent of tissue viability obtained by a biopsy of the relevant myocardial regions at the time of coronary artery bypass surgery. In these studies, it has been demonstrated that quantitative analysis of tracer uptake correlates directly with the magnitude of preservation of tissue viability (372,378-380). Many studies in the literature evaluate the techniques for assessing viability by assigning a specific threshold or cutpoint, often 50 or 60% of maximum tracer uptake, to create dichotomous performance characteristics (sensitivity, specificity, and positive and negative predictive values). An important principle illustrated by the biopsy studies is that tracer uptake represents a continuous variable, with the magnitude of tracer uptake directly reflecting the magnitude of preserved viability. In turn, the magnitude of tracer uptake is linked to the probability of regional functional recovery after revascularization (381,382).Ñ òåõ ïîð, êàê âûøëè ýòè ãàéäû îñíîâíûå ïðèíöèïû èíòåðïðåòàöèè ðåçóëüòàòîâ ñöèíòèãðàôèè íå èçìåíèëècü. Íà íèõ-òî ìû è îñòàíîâèìñÿ.
1- åñëè íàêîïëåíèå èíäèêàòîðà â ìèîêàðäå íå ìíååå 50 % - ìèîêàðä (ó áîëüíûõ ÈÁÑ!) àáñîëþòíî æèçíåñïîñîáåí.
2- Ïðè ñíèæåíèè äî 60% (à ñåé÷àñ íåêîòîðûå àâòîðû ñ÷èòàþò è äî 69%) îò ìàêñèìóìà – óñëîâíî æèçíåñïîñîáåí
3- Ïðè ñíèæåíèè äî 70% è áîëåå ìèîêàðä íå æèçíåñïîñîáåí.
Ïîýòîìó, åñëè âàì ãîâîðÿò îá îöåíêå æèçíåñïîñîáíîãî ìèîêàðäà ïðè íàãðóçêå â ñëó÷àå ñöèíòèãðàôèè
Öèòàòà:
Ñîîáùåíèå îò corvalol Ïîñìîòðåòü ñîîáùåíèå
äà õîòü ê íàì. ê ñëîâó ó íàñ äëÿ òàêîé îöåíêè äåëàþò íà ïðîñòî ñöèíòèãðàôèþ, à ÑÎÝÊÒ ìèîêàðäà (3-4 ìåðíîå èññëåäîâàíèå ñ îöåíêîé ïåðôóçèè è ñîêðàòèìîñòè â ïîêîå è ïîä íàãðóçêîé)
ìîè êîíòàêòû â ëè÷íûõ äàííûõ - çâîíèòå åñëè ÷òî!
– âàñ ïðîñòî îáìàíûâàþò, ëèáî, çàîäíî, îáìàíûâàþò è ñàìèõ ñåáÿ.
Íèêàêîé íàãðóçêè çäåñü íå íàäî.
 íàøåì ñëó÷àå õèðóðãè òðåáîâàëè ïîäòâåðäèòü èëè îïðîâåðãíóòü çàêëþ÷åíèå ÌÐÒ ñ êîíòðàñòîì: «ðóáöîâûå èçìåíåíèÿ íà âåðõóøêå, ïåðåäíåé, áîêîâîé íèæíåé ñòåíêàõ, òðàíñìóðàëüíîå ðàñïðîñòðàíåíèå äî 70%." Ñõåìàòè÷åñêè ó íàøåãî áîëüíîãî ïðè àâòîìàòè÷åñêîé ïîëóêîëè÷åñòâåííîé îöåíêå ýòî âûãëÿäåëî âîò òàê: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Êàêèå áóäóò ìíåíèÿ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #57  
Ñòàðûé 26.09.2009, 17:42
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Åñëè äðóãèõ ìíåíèé íå áóäåò, ðàçðåøèòå ïðîäîëæèòü èçëîæåíèå ñèòóàöèè. Íà ïðåäñòàâëåííîì ðèñóíêå ÿ îáâåë áåëûì ïóíêòèðîì î÷àãè, êîòîðûå ìîæíî îòíåñòè ê íåæèçíåñïîñîáíûì ïî ïðèíöèïàì, èçëîæåííûì â ãàéäàõ è öèòèðîâàííûì ðàíåå.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Âèäíû äâà òàêèõ î÷àãà. Îäèí - íà âåðõóøêå ñ ðàñïðîñòðàíåíèåì íà ïåðåäíþþ ñòåíêó ìåíåå ÷åì íà åå àïèêàëüíóþ òðåòü. Âòîðîé – çàäíåáàçàëüíûå îòäåëû ñ ïåðåõîäîì íà çàäíåáîêîâóþ ñòåíêó. Ñðàâíèì ýòî ñ òåì, ÷òî íàïèñàíî â âûïèñêå ïî ðåçóëüòàòàì ÌÐÒ …Èøåìè÷åñêèå èçìåíåíèÿ ËÆ: ðóáöîâûå èçìåíåíèÿ íà âåðõóøêå ïåðåäíåé áîêîâîé íèæíåé ñòåíêàõ, òðàíñìóðàëüíîå ïîðàæåíèå äî 70%… Ñ îäíîé ñòîðîíû, óïîìÿíóòû âðîäå òå æå ñòåíêè è ïðîöåíòû íàðóøåíèé ïåðôóçèè ïî ïîëóêîëè÷åñòâåííîé îöåíêå ñîâïàäàþò ( íå îáÿçàòåëüíî ýòî òðàíñìóðàëüíûå ïîðàæåíèÿ!). Íî, ïîñìîòðèòå íà ðàäèîíóêëèäíûå èçîáðàæåíèÿ ïåðôóçèè: 1- ðàçâå çîíû îòìå÷åííûå áåëûì ïóíêòèðîì (òî åñòü íåæèçíåñïîñîáíûé ìèîêàðä) çàíèìàþò 70% ïëîùàäè âñåãî ìèîêàðäà? 2 - Ðàçâå áόëüøàÿ (óäàðåíèå íà î) ÷àñòü ïåðåäíåé ñòåíêè íå ðåäñòàâëåíà æèçíåñïîñîáíûì ìèîêàðäîì? 3- Ðàçâå âñÿ ïåðåäíåáîêîâàÿ ñòåíêà íå ïðåäñòàâëåíà æèçíåñïîñîáíûì ìèîêàðäîì? 4- Ðàçâå ÌÆÏ è ïåðåäíåïåðåãîðîäî÷íûå îòäåëû íå ïðåäñòàâëåíû æèçíåñïîñîáíûì ìèîêàðäîì?

Êîììåíòàðèè ê ñîîáùåíèþ:
LupusDoc îäîáðèë(à): Ñïàñèáî çà íàãëÿäíûé ïðèìåð. Íå ìîãëè áû Âû ïîÿñíèòü îòíîøåíèå ê íàãðóçî÷íîé ñöèíòè?
Yariko îäîáðèë(à): Ñïàñèáî, ïîó÷èòåëüíî
Îòâåòèòü ñ öèòèðîâàíèåì
  #58  
Ñòàðûé 26.09.2009, 19:25
Àâàòàð äëÿ corvalol
corvalol corvalol âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.07.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 253
Ñêàçàë(à) ñïàñèáî: 5
Ïîáëàãîäàðèëè 29 ðàç(à) çà 29 ñîîáùåíèé
corvalol ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
â ëþáîì ñëó÷àå ÿ áû ïîñìîòðåë ãëóáèíó (severity) äåôåêòîâ ïåðôóçèè - ýòî 1.
à 2 - íàäî ñìîòðåòü íà ñîêðàòèìîñòü!
èìõî òóò íå âñå â ïîðÿäêå ñ íèæíå - ïåðåãîðîäî÷íûì ñåãìåíòîì (ñðåäíÿÿ ñòåïåíü íàðóøåíèé ïåðôóçèè) è âåðõóøå÷íî-íèæíèì!
è êñòàòè êàêîé òèï êîðîíàðíîãî êðîâîòîêà ó ïàöèåíòà ëåâûé èëè ïðàâûé?
Îòâåòèòü ñ öèòèðîâàíèåì
  #59  
Ñòàðûé 26.09.2009, 19:47
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò corvalol Ïîñìîòðåòü ñîîáùåíèå
â ëþáîì ñëó÷àå ÿ áû ïîñìîòðåë ãëóáèíó (severity) äåôåêòîâ ïåðôóçèè - ýòî 1.?
Èìåííî äëÿ òîãî, ÷òîáû âñå ìîãëè ïîñìîòðåòü ãëóáèíó è ðàñïðîñòðàíåííîñòü äåôåêòîâ ïåðôóçèè ÿ è ïðèâåë "Áû÷èé ãëàç" ïåðôóçèîííîé ÎÝÊÒ âìåñòå ñ öèôðîâîé øêàëîé. Íåóæåëè Âû ñ íèìè íå çíàêîìû?
Öèòàòà:
Ñîîáùåíèå îò corvalol Ïîñìîòðåòü ñîîáùåíèå
à 2 - íàäî ñìîòðåòü íà ñîêðàòèìîñòü!.
Èìåííî äëÿ ýòîãî ÿ è ïðèâåë ãàéäû, è íåïîñðåäñòâåííî öèòèðîâàë îñíîâíûå ïðèíöèïû èíòåðïðåòàöèè ñöèíòèãðàìì ïðè îöåíêå æèçíåñïîñîáíîñòè. Ãäå â ãàéäàõ Âû óâèäåëè îöåíêó ñîêðàòèìîñòè ïðè âûÿâëåíèè æèçíåñïîñîáíîñòè ïî ïåðôóçèîííûì ñöèíòèãðàììàì? Ïðåäëàãàåòå AHA, ACC è ASCN âíåñòè èçìåíåíèÿ â ãàéäû?
Öèòàòà:
Ñîîáùåíèå îò corvalol Ïîñìîòðåòü ñîîáùåíèå
èìõî òóò íå âñå â ïîðÿäêå ñ íèæíå - ïåðåãîðîäî÷íûì ñåãìåíòîì (ñðåäíÿÿ ñòåïåíü íàðóøåíèé ïåðôóçèè) è âåðõóøå÷íî-íèæíèì!?
Ãäå æå Âû ðàíüøå áûëè, êîãäà ÿ ñïðàøèâàë êàêèå áóäóò ìíåíèÿ?
Èìåííî äëÿ òîãî, ÷òîáû Âû óâèäåëè çîíû íåæèçíåñïîñîáíîãî ìèîêàðäà ÿ è îáâåë áåëûì ïóíêòèðîì çîíû ñîîòâåòñòâóþùèå íåæèçíåñïîñîáíîìó ìèîêàðäó ñîîòâåòñòâåííî èíòåðïðåòàöèè ïî ãàéäàì.
Öèòàòà:
Ñîîáùåíèå îò corvalol Ïîñìîòðåòü ñîîáùåíèå
è êñòàòè êàêîé òèï êîðîíàðíîãî êðîâîòîêà ó ïàöèåíòà ëåâûé èëè ïðàâûé?
Ê ñîæàëåíèþ, ýòî, ïîêà ÷òî, íå êñòàòè, ïîñêîëüêó ðå÷ü èäåò îá îöåíêå æèçíåñïîñîáíîñòè ïî ïåðôóçèîííûì ñöèíòèãðàììàì. Èçâèíèòå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #60  
Ñòàðûé 26.09.2009, 19:57
Àâàòàð äëÿ ostroumov
ostroumov ostroumov âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.04.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 407
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 29 ðàç(à) çà 28 ñîîáùåíèé
ostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåostroumov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò LupusDoc
Ñïàñèáî çà íàãëÿäíûé ïðèìåð. Íå ìîãëè áû Âû ïîÿñíèòü îòíîøåíèå ê íàãðóçî÷íîé ñöèíòè?
Óâàæàåìàÿ LupusDoc! Ôóíêöèîíàëüíûå òåñòû ïðè ïðîâåäåíèè ñöèíòèãðàôèè ìèîêàðäà ðàñïðîñòðàíåíû äîñòàòî÷íî øèðîêî. Îíè áûâàþò ðàçíûå è çàâèñÿò îò öåëè âûáðàííîãî èññëåäîâàíèÿ, óñëîâèé â êîòîðûõ ïðîâîäèòñÿ èññëåäîâàíèå è âîçìîæíîñòåé ïàöèåíòà. ß èõ î÷åíü ëþáëþ. Îäíàêî, îöåíêà æèçíåñïîñîáíîñòè, ñîîòâåòñòâåííî ïðèâåäåííûì ìíîþ ãàéäàì, íå òðåáóåò ïðîâåäåíèÿ ôóíêöèîíàëüíûõ òåñòîâ ïðè ñöèíòèãðàôèè ìèîêàðäà, êàê ÿ óæå ïèñàë âûøå.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 13:06.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.